Breakthrough drug may give hope to kidney patients rejected for transplant
NCT ID NCT05369975
First seen Apr 25, 2026 · Last updated Jun 16, 2026 · Updated 11 times
Summary
This study tested a drug called imlifidase in 113 highly sensitized kidney patients who had a positive crossmatch against a deceased donor. The drug was given before transplant to reduce the risk of rejection. The main goal was to see how many patients still had a working kidney one year after transplant. Results were compared to less sensitized patients who did not receive the drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANTATION IN HIGHLY SENSITIZED PATIENTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Azienda Ospedaliera di Padova
Padova, 35128, Italy
-
Azienda Ospedaliero - Universitaria di Parma
Parma, 43100, Italy
-
CHU de Grenoble - Hôpital Michallon
La Tronche, 38700, France
-
Centre Hospitalier Universitaire (CHU) de Rouen - Hôpital de Bois-Guillaume
Bois-Guillaume, 76230, France
-
Charité - Universitätsmedizin Berlin
Berlin, 13353, Germany
-
Department of Nephrology , Zaloška 7
Ljubljana, 1000, Slovenia
-
Erasmus University Medical Center
Rotterdam, 3015 GD, Netherlands
-
Hospital 12 de Octubre
Madrid, 28041, Spain
-
Hospital Clínic de Barcelona, Unidad de Trasplante Renal
Barcelona, 08036, Spain
-
Hospital Del Mar, Servicio de Nefrología
Barcelona, 08003, Spain
-
Hôpital Necker - Enfants Malades
Paris, 75015, France
-
Institut klinicke a experimentalni mediciny (IKEM)
Prague, 140-21, Czechia
-
Karolinska University Hospital
Huddinge, 141 57, Sweden
-
Klinikum rechts der Isar der Technische Universitaet Muenchen
Munich, 81675, Germany
-
Leicester General Hospital
Leicester, LE5 4PW, United Kingdom
-
Leiden University Medical Center
Leiden, 2333 ZA, Netherlands
-
Medizinische Universitaet Wien
Vienna, 1090, Austria
-
St. James University Hospital
Leeds, LS9 7TF, United Kingdom
-
UZ Leuven - Campus Gasthuisberg
Leuven, 3000, Belgium
-
University Medical Center Groningen
Groningen, 9713, Netherlands
-
Uppsala University Hospital
Uppsala, 751 85, Sweden
-
Vall d'Hebron University Hospital (HUVH)
Barcelona, Spain
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.